Biogen Idec Ramps Up For BG-12, Dubs The MS Drug Tecfidera
This article was originally published in The Pink Sheet Daily
Executive Summary
The biopharma released the new name and cited a rough pricing range for multiple sclerosis drug BG-12, which has a late March PDUFA date. But management tapped the brakes a bit on analyst sales estimates, offering a few words of caution.